Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this trial is to further evaluate the efficacy and safety of
deferasirox, dosed initially according to the transfusional iron intake, in patients with
transfusion dependant anemia related to disorders other than β-thalassemia and sickle cell
disease.
During the study, the dose will be adjusted based on serum Ferritin.The overall purpose of
the extension is to allow further treatment of patients who have already completed the core
study, and to enable collection of long term efficacy and safety data. Patients will continue
to receive Deferasirox at the dose they received at the end of the core study.